Vnitr Lek 2016, 62(2):107-113

AT1-blockers in the treatment of hypertension: summary

Jiří Widimský jr
III. interní klinika 1. LF UK a VFN, Praha

Angiotensin receptor antagonists (AT1-blockers) are considered as one of the major classes of antihypertensive drugs suitable for monotherapy as well as for combination treatment. AT1-blockers have comparable antihypertensive efficacy with other major classes of antihypertensive drugs. AT1-blockers are considered by current guidelines of Czech society of hypertension altogether with ACE-inhibitors and calcium channel blockers as universal antihypertensive drug class. AT1-blockers has the lowest profile of side-effects among all antihypertensive drug classes and thus very high persistence to therapy. Mechanisms of antihypertensive effects of AT1-blockers are discussed altogether with the results of large clinical trials and indications in the treatment of hypertension.

Keywords: AT1-blockers; hypertension; treatment

Received: January 14, 2016; Accepted: January 25, 2016; Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J. AT1-blockers in the treatment of hypertension: summary. Vnitr Lek. 2016;62(2):107-113.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kaplan N. Victor RG. Kaplan's Clinical Hypertension. 11th ed. Lippincott Williams and Wilkins: 2014. ISBN 978-1451190137.
    2. Slíva J. Sartany v léčbě hypertenze. Acta medicinae 2015; 8: 2-7.
    3. Kakuta H, Sudoh K, Sasamata M et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25(1): 41-46.
    4. Weber MA. Angiotensin receptor blockers. In Izzo JL, Sica DA, Black R et al. Hypertension Primer: The Essentials of High Blood Pressure, Basic Science, Population Science, And Clinical Management. 4th ed. Lippincott Williams and Wilkins: 2007: 461-464. ISBN 978-0781782050.
    5. Williams B, Lacourcière Y, Schumacher H et al. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens 2009; 23(9): 610-619. Go to original source... Go to PubMed...
    6. Conlin PR, Spence JD, Wiliams B et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13(4 Pt 1): 418-426. Go to original source... Go to PubMed...
    7. Fabia MJ, Abdilla N, Oltra R et al. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25(7): 1327-1336. Go to original source... Go to PubMed...
    8. Bakris GL, Sica D, Weber M et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011; 13(2): 81-88. Go to original source... Go to PubMed...
    9. Neldam S, Edwards C, Jones R. TEAMSTA-10 Investigators. Switching patiens with uncotnrolled hypertension on amlodipin 10 mg to single-pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study. Curr Med Res Opin 2011; 27(11): 1-9. Go to original source... Go to PubMed...
    10. Rakugi H, Ogihara T, Miyata Y et al. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2012; 34(4): 838-848. Go to original source... Go to PubMed...
    11. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15): 1547-1559. Go to original source... Go to PubMed...
    12. Filipovský J, Widimský J jr, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze-verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58(10): 785-801. Go to PubMed...
    13. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281-1357. Go to original source... Go to PubMed...
    14. Fried LF, Emanuele N, Zhang JH et al (VA NEPHRON-D Investigators). Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369(20): 1892-1903. Go to original source... Go to PubMed...
    15. Brenner BM, Cooper ME, de Zeeuw D et al (RENAAL Study Investigators). Effects of losartan on renal and cardiovascular outcomes in patients with type-2 diabetes and nephropathy. N Engl J Med 2001; 345(12): 861-869. Go to original source... Go to PubMed...
    16. Parving HH, Lehnert H, Bröchner-Mortensen J et al. Irbesartan in Patients with Type-2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type-2 diabetes. N Engl J Med 2001; 345(12): 870-878. Go to original source... Go to PubMed...
    17. Lewis EJ, Hunsicker LG, Clarke WR et al (Collaborative Study Group). Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851-860. Go to original source... Go to PubMed...
    18. Dahlöf B, Devereux RB, Kjeldsen SE et al (LIFE Study Group). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359(9311): 995-1003. Go to original source... Go to PubMed...
    19. Lithell H, Hansson L, Skoog I et al (SCOPE Study Group). The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21(5): 875-886. Go to original source... Go to PubMed...
    20. Julius S, Kjeldsen SE, Weber M et al (VALUE Trial Group). Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022-2031. Go to original source... Go to PubMed...
    21. Schrader J, Luders S, Kulschewski A et al (MOSES Study Group). Morbidity and Mortality After Stroke. Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36(6): 1218-2126. Go to original source... Go to PubMed...
    22. Yusuf S, Diener HC, Sacco RL et al. Telmisartan to prevent recurrent stroke and cardiovascular events, Profess study. N Engl J Med 2008; 359(12):1225-1237. Go to original source... Go to PubMed...
    23. Petrella RJ, Shlyakhto E, Konradi AO et al. Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) study. J Clin Hypertens 2012; 14(2): 78-84. Go to original source... Go to PubMed...
    24. Barnett AH, Bain SC, Bouter P et al.:Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351(19):1952-1961. Go to original source... Go to PubMed...
    25. Špinar J, Vítovec J, Souček M et al. CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers. Vnitř Lék 2009; 55(5): 481-488. Go to PubMed...
    26. Shih CJ, Chen HT, Chao PW et al. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.. J Hypertens 2015. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0000000000000804> Go to original source... Go to PubMed...
    27. Mancia G, Seravalle G, Grassi G. Tolerability and treatment compliance with angiotensin II receptor antagonists. Am J Hypertens 2003; 16(12): 1066-1073. Go to original source... Go to PubMed...
    28. Corrao G, Zambon A, Parodi A et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens, 2008: 26(4) :819-824. Go to original source... Go to PubMed...
    29. Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment: a review. Cardiovasc Diabetol 2009; 8:18. Dostupné z DOI: <http://dx.doi.org/10.1186/1475-2840-8-18>. Go to original source... Go to PubMed...
    30. Gosmanova EO, Lu JL, Streja E et al. Association of medical treatment nonadherence with all-cause mortality in newly treated hypertensive US veterans. Hypertension 2014; 64(5): 951-957. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.